HC Wainwright & Co. Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 87.2%

Neg 87.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Neutral and lowers the price target from $48 to $41.